Celldex Therapeutics, Inc. (CLDX) Operating income 2016–2025
Celldex Therapeutics, Inc. (CLDX) annual operating income history from SEC filings — each fiscal year as reported.
-$287.4MFY2025 · since FY2016: -$132.9M → -$287.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$287.4M | -47.3% |
| FY2024 | -$195.1M | -26.2% |
| FY2023 | -$154.5M | -34.1% |
| FY2022 | -$115.2M | -61.7% |
| FY2021 | -$71.2M | -12.5% |
| FY2020 | -$63.4M | -15.1% |
| FY2019 | -$55.0M | +64.8% |
| FY2018 | -$156.4M | -28.7% |
| FY2017 | -$121.5M | +8.6% |
| FY2016 | -$132.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CLDX financial trends
CLDX RevenueCLDX Net incomeCLDX Net marginCLDX Gross profitCLDX Gross marginCLDX Operating marginCLDX Operating cash flowCLDX Free cash flowCLDX Capital expendituresCLDX Return on equityCLDX Stock buybacksCLDX Dividends paidCLDX Total assetsCLDX Total liabilitiesCLDX Shareholders’ equityCLDX overview →